Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced Solid Tumors Cancer Clear all
Completed Phase 1 Interventional

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

NCT00980239
View directory record Official record
Conditions
Liver Cancer, Advanced Cancer
Interventions
Irinotecan, Bevacizumab, Oxaliplatin, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

NCT04050709
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Interventions
PD-L1 t-haNK
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

NCT02620839
View directory record Official record
Conditions
Solid Tumors
Interventions
Alpelisib, Cisplatin
Drug
Lead sponsor
Pamela Munster
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

NCT01011972
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
XMT-1107
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06307795
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
ANS014004
Drug
Lead sponsor
Avistone Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Study in Adult Subjects With Select Advanced Solid Tumors

NCT02583165
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI1873
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Active, not recruiting Phase 1 Interventional

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT03889795
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions
Metformin, Simvastatin, Digoxin
Drug
Lead sponsor
Danae Hamouda, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Results available

QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

NCT03027128
View directory record Official record
Conditions
Solid Tumor
Interventions
haNK™ for Infusion
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

NCT01458067
View directory record Official record
Conditions
Cancer
Interventions
GSK2636771
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
New Haven, Connecticut • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

NCT05948865
View directory record Official record
Conditions
Cancer, Cancer, Lung
Interventions
CPO301
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

NCT00116896
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-7904L, Cisplatin
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

NCT01494688
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Paclitaxel, RO5509554
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

NCT01673737
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR260301, Vemurafenib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

NCT04252339
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
RLY-1971
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04840394
View directory record Official record
Conditions
Tumor, Solid
Interventions
BDB018, Pembrolizumab
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

NCT04266912
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Avelumab, Berzosertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Active, not recruiting Phase 1 Interventional

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

NCT05163028
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions
HBI-2376
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Duarte, California • Encinitas, California • Fullerton, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
WTX-124, pembrolizumab
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NCT01055795
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Bevacizumab, Everolimus and LBH589
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04196283
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 24, 2026, 4:03 PM EDT